This page in English
Laddar profil information

Publikationer

Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis
Frisell T, Forsberg L, Nordin N, Kiesel C, Alfredsson L, Askling J, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2016;22(1):85-93

Genetic analysis of the isolated Faroe Islands reveals SORCS3 as a potential multiple sclerosis risk gene
Binzer S, Stenager E, Binzer M, Kyvik Ko, Hillert J, Imrell K
MULTIPLE SCLEROSIS JOURNAL 2016;22(6):733-740

Multiple sclerosis and risk of young-adult-onset Hodgkin lymphoma
Montgomery S, Hajiebrahimi M, Burkill S, Hillert J, Olsson T, Bahmanyar S
Neurology® neuroimmunology & neuroinflammation 2016;3(3):e227-

A 10-year population-based study of people with multiple sclerosis in Stockholm, Sweden: use of and satisfaction with care and the value of different factors in predicting use of care
Chruzander C, Johansson S, Gottberg K, Einarsson U, Hillert J, Holmqvist Lw, et al
BMC health services research 2015;15():480-

Age-dependent effects on the treatment response of natalizumab in MS patients
Matell H, Lycke J, Svenningsson A, Holmen C, Khademi M, Hillert J, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2015;21(1):48-56

All-cause mortality following a cancer diagnosis amongst multiple sclerosis patients: a Swedish population-based cohort study
Roshanisefat H, Bahmanyar S, Hillert J, Olsson T, Montgomery S
European journal of neurology 2015;22(7):1074-80

A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis
Gu Bj, Field J, Dutertre S, Ou A, Kilpatrick Tj, Lechner-scott J, et al
Human molecular genetics 2015;24(19):5644-54

Class II HLA interactions modulate genetic risk for multiple sclerosis
Moutsianas L, Jostins L, Beecham Ah, Dilthey At, Xifara Dk, Ban M, et al
Nature genetics 2015;47(10):1107-13

Earnings and Financial Compensation from Social Security Systems Correlate Strongly with Disability for Multiple Sclerosis Patients
Kavaliunas A, Wiberg M, Tinghog P, Glaser A, Gyllensten H, Alexanderson K, et al
PloS one 2015;10(12):e0145435-

Effect of Smoking Cessation on Multiple Sclerosis Prognosis
Ramanujam R, Hedstrom Ak, Manouchehrinia A, Alfredsson L, Olsson T, Bottai M, et al
JAMA neurology 2015;72(10):1117-23

Genetic variants are major determinants of CSF antibody levels in multiple sclerosis
Goris A, Pauwels I, Gustavsen Mw, Van Son B, Hilven K, Bos Sd, et al
Brain : a journal of neurology 2015;138(Pt 3):632-43

Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis
Sundal C, Baker M, Karrenbauer V, Gustavsen M, Bedri S, Glaser A, et al
European journal of neurology 2015;22(2):328-33

High inbreeding in the Faroe Islands does not appear to constitute a risk factor for multiple sclerosis
Binzer S, Imrell K, Binzer M, Kyvik Ko, Hillert J, Stenager E
Multiple sclerosis (Houndmills, Basingstoke, England) 2015;21(8):996-1002

Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort
Westerlind H, Imrell K, Ramanujam R, Myhr Km, Celius Eg, Harbo Hf, et al
European journal of human genetics : EJHG 2015;23(5):688-92

Is disability pension a risk indicator for future need of psychiatric healthcare or suicidal behavior among MS patients- a nationwide register study in Sweden?
Bjorkenstam C, Tinghog P, Brenner P, Mittendorfer-rutz E, Hillert J, Jokinen J, et al
BMC psychiatry 2015;15():286-

Obesity interacts with infectious mononucleosis in risk of multiple sclerosis
Hedstrom Ak, Lima Bomfim I, Hillert J, Olsson T, Alfredsson L
European journal of neurology 2015;22(3):578-e38

Sources and level of income among individuals with multiple sclerosis compared to the general population: A nationwide population-based study
Wiberg M, Friberg E, Stenbeck M, Alexanderson K, Norlund A, Hillert J, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2015;21(13):1730-41

The influence of immunomodulatory treatment on the clinical course of multiple sclerosis
Kavaliunas A, Stawiarz L, Hedbom J, Glaser A, Hillert J
Advances in experimental medicine and biology 2015;822():19-24

The Swedish MS registry – clinical support tool and scientific resource
Hillert J, Stawiarz L
Acta neurologica Scandinavica 2015;132(199):11-9

Alcohol as a modifiable lifestyle factor affecting multiple sclerosis risk
Hedstrom Ak, Hillert J, Olsson T, Alfredsson L
JAMA neurology 2014;71(3):300-5

Co-morbidities increase the risk of disability pension among MS patients: a population-based nationwide cohort study
Tinghog P, Bjorkenstam C, Carstensen J, Jansson C, Glaser A, Hillert J, et al
BMC neurology 2014;14():117-

Cytomegalovirus seropositivity is negatively associated with multiple sclerosis
Sundqvist E, Bergstrom T, Daialhosein H, Nystrom M, Sundstrom P, Hillert J, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2014;20(2):165-73

[Every fifth case of multiple sclerosis is familial]
Binzer S, Binzer M, Kyvik Ko, Imrell K, Hillert J, Stenager E
Ugeskrift for laeger 2014;176(3A):V04130245-

HLA-A(∗)02, gender and tobacco smoking, but not multiple sclerosis, affects the IgG antibody response against human herpesvirus 6
Engdahl E, Gustafsson R, Ramanujam R, Sundqvist E, Olsson T, Hillert J, et al
Human immunology 2014;75(6):524-30

Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis
Link J, Lundkvist Ryner M, Fink K, Hermanrud C, Lima I, Brynedal B, et al
PloS one 2014;9(3):e90479-

Interferon beta treatment of multiple sclerosis increases serum interleukin-7
Lundstrom W, Hermanrud C, Sjostrand M, Brauner S, Wahren-herlenius M, Olsson T, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2014;20(13):1727-36

JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants
Sundqvist E, Buck D, Warnke C, Albrecht E, Gieger C, Khademi M, et al
PLoS pathogens 2014;10(4):e1004084-

Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden
Westerlind H, Ramanujam R, Uvehag D, Kuja-halkola R, Boman M, Bottai M, et al
Brain : a journal of neurology 2014;137(Pt 3):770-8

Multiple sclerosis and psychiatric disorders: comorbidity and sibling risk in a nationwide Swedish cohort
Johansson V, Lundholm C, Hillert J, Masterman T, Lichtenstein P, Landen M, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2014;20(14):1881-91

Multiple sclerosis clinical course and cardiovascular disease risk - Swedish cohort study
Roshanisefat H, Bahmanyar S, Hillert J, Olsson T, Montgomery S
European journal of neurology 2014;21(11):1353-e88

Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy
Ferreira D, Voevodskaya O, Imrell K, Stawiarz L, Spulber G, Wahlund Lo, et al
Journal of neuroimmunology 2014;274(1-2):149-54

Multiple sclerosis registries in Europe - results of a systematic survey
Flachenecker P, Buckow K, Pugliatti M, Kes Vb, Battaglia Ma, Boyko A, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2014;20(11):1523-32

New data identify an increasing sex ratio of multiple sclerosis in Sweden
Westerlind H, Bostrom I, Stawiarz L, Landtblom Am, Almqvist C, Hillert J
Multiple sclerosis (Houndmills, Basingstoke, England) 2014;20(12):1578-83

Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general
Gustavsen Mw, Viken Mk, Celius Eg, Berge T, Mero Il, Berg-hansen P, et al
Journal of neuroimmunology 2014;274(1-2):174-9

Psychiatric diagnoses, medication and risk for disability pension in multiple sclerosis patients; a population-based register study
Brenner P, Alexanderson K, Bjorkenstam C, Hillert J, Jokinen J, Mittendorfer-rutz E, et al
PloS one 2014;9(8):e104165-

Reply: Shared environmental effects on multiple sclerosis susceptibility: conflicting evidence from twin studies
Westerlind H, Kuja-halkola R, Ramanujam R, Hillert J
Brain : a journal of neurology 2014;137(Pt 7):e288-

Reverse causality behind the association between reproductive history and MS
Hedstrom Ak, Hillert J, Olsson T, Alfredsson L
Multiple sclerosis (Houndmills, Basingstoke, England) 2014;20(4):406-11

Smokers run increased risk of developing anti-natalizumab antibodies
Hedstrom Ak, Alfredssoni L, Ryner Ml, Fogdell-hahn A, Hillert J, Olsson T
MULTIPLE SCLEROSIS JOURNAL 2014;20(8):1081-1085

Smoking and risk of treatment-induced neutralizing antibodies to interferon β-1a
Hedstrom Ak, Ryner M, Fink K, Fogdell-hahn A, Alfredsson L, Olsson T, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2014;20(4):445-50

Variability in the CIITA gene interacts with HLA in multiple sclerosis
Gyllenberg A, Piehl F, Alfredsson L, Hillert J, Bomfim Il, Padyukov L, et al
Genes and immunity 2014;15(3):162-7

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
International Multiple Sclerosis Genetics Consortium (imsgc), Beecham Ah, Patsopoulos Na, Xifara Dk, Davis Mf, Kemppinen A, et al
Nature genetics 2013;45(11):1353-60

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort
Olsson T, Achiron A, Alfredsson L, Berger T, Brassat D, Chan A, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2013;19(11):1533-8

Changes to anti-JCV antibody levels in a Swedish national MS cohort
Warnke C, Ramanujam R, Plavina T, Bergstrom T, Goelz S, Subramanyam M, et al
Journal of neurology, neurosurgery, and psychiatry 2013;84(11):1199-205

Characterization of anti-natalizumab antibodies in multiple sclerosis patients
Lundkvist M, Engdahl E, Holmen C, Moverare R, Olsson T, Hillert J, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2013;19(6):757-64

Considerations for subgroups and phenocopies in complex disease genetics
Ramanujam R, Ramanujam S, Hillert J
PloS one 2013;8(8):e71614-

Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome
Comi G, Martinelli V, Rodegher M, Moiola L, Leocani L, Bajenaru O, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2013;19(8):1074-83

Exposure to anaesthetic agents does not affect multiple sclerosis risk
Hedstrom Ak, Hillert J, Olsson T, Alfredsson L
European journal of neurology 2013;20(5):735-9

High prevalence of sickness absence and disability pension among multiple sclerosis patients: a nationwide population-based study
Tinghog P, Hillert J, Kjeldgard L, Wiberg M, Glaser A, Alexanderson K
Multiple sclerosis (Houndmills, Basingstoke, England) 2013;19(14):1923-30

Hospital admission due to infections in multiple sclerosis patients
Montgomery S, Hillert J, Bahmanyar S
European journal of neurology 2013;20(8):1153-60

Impact of cerebrospinal-fluid oligoclonal immunoglobulin bands and HLA-DRB1 risk alleles on brain magnetic-resonance-imaging lesion load in Swedish multiple sclerosis patients
Karrenbauer Vd, Prejs R, Masterman T, Hillert J, Glaser A, Imrell K
Journal of neuroimmunology 2013;254(1-2):170-3

In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106
Takano A, Piehl F, Hillert J, Varrone A, Nag S, Gulyas B, et al
EJNMMI research 2013;3(1):30-

Mortality following a brain tumour diagnosis in patients with multiple sclerosis
Montgomery S, Hassan A, Bahmanyar S, Brus O, Hussein O, Hiyoshi A, et al
BMJ open 2013;3(11):e003622-

Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls
International Multiple Sclerosis Genetics Consortium
American journal of human genetics 2013;92(6):854-65

Nicotine might have a protective effect in the etiology of multiple sclerosis
Hedstrom Ak, Hillert J, Olsson T, Alfredsson L
Multiple sclerosis (Houndmills, Basingstoke, England) 2013;19(8):1009-13

Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles
Mero Il, Gustavsen Mw, Saether Hs, Flam St, Berg-hansen P, Sondergaard Hb, et al
PloS one 2013;8(3):e58352-

Smoking and multiple sclerosis susceptibility
Hedstrom Ak, Hillert J, Olsson T, Alfredsson L
European journal of epidemiology 2013;28(11):867-74

Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity
Lundstrom W, Highfill S, Walsh St, Beq S, Morse E, Kockum I, et al
Proceedings of the National Academy of Sciences of the United States of America 2013;110(19):E1761-70

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs
Tedeholm H, Lycke J, Skoog B, Lisovskaja V, Hillert J, Dahle C, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2013;19(6):765-74

A genome-wide association study in progressive multiple sclerosis
Martinelli-boneschi F, Esposito F, Brambilla P, Lindstrom E, Lavorgna G, Stankovich J, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2012;18(10):1384-94

Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS
Pugliatti M, Eskic D, Mikolcic T, Pitschnau-michel D, Myhr Km, Sastre-garriga J, et al
Acta neurologica Scandinavica. Supplementum 2012;(195):24-30

Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans
Brambilla P, Esposito F, Lindstrom E, Sorosina M, Giacalone G, Clarelli F, et al
Neuroscience letters 2012;530(2):155-60

Epstein-Barr virus and multiple sclerosis: interaction with HLA
Sundqvist E, Sundstrom P, Linden M, Hedstrom Ak, Aloisi F, Hillert J, et al
Genes and immunity 2012;13(1):14-20

Evolution of microglial activation in ischaemic core and peri-infarct regions after stroke: a PET study with the TSPO molecular imaging biomarker [((11))C]vinpocetine
Gulyas B, Toth M, Schain M, Airaksinen A, Vas A, Kostulas K, et al
Journal of the neurological sciences 2012;320(1-2):110-7

Importance of human leukocyte antigen (HLA) class I and II alleles on the risk of multiple sclerosis
Link J, Kockum I, Lorentzen Ar, Lie Ba, Celius Eg, Westerlind H, et al
PloS one 2012;7(5):e36779-

Lack of replication of interaction between EBNA1 IgG and smoking in risk for multiple sclerosis
Sundqvist E, Sundstrom P, Linden M, Hedstrom Ak, Aloisi F, Hillert J, et al
Neurology 2012;79(13):1363-8

Placebo-controlled trial of oral laquinimod for multiple sclerosis
Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca Ma, et al
The New England journal of medicine 2012;366(11):1000-9

Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice
Jungedal R, Lundkvist M, Engdahl E, Ramanujam R, Westerlind H, Sominanda A, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2012;18(12):1775-81

Shared genetic factors may not explain the raised risk of comorbid inflammatory diseases in multiple sclerosis
Roshanisefat H, Bahmanyar S, Hillert J, Olsson T, Montgomery S
Multiple sclerosis (Houndmills, Basingstoke, England) 2012;18(10):1430-6

Sunlight is associated with decreased multiple sclerosis risk: no interaction with human leukocyte antigen-DRB1*15
Baarnhielm M, Hedstrom Ak, Kockum I, Sundqvist E, Gustafsson Sa, Hillert J, et al
European journal of neurology 2012;19(7):955-62

Visualising neuroinflammation in post-stroke patients: a comparative PET study with the TSPO molecular imaging biomarkers [11C]PK11195 and [11C]vinpocetine
Gulyas B, Toth M, Vas A, Shchukin E, Kostulas K, Hillert J, et al
Current radiopharmaceuticals 2012;5(1):19-28

Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655
Sondergaard Hb, Sellebjerg F, Hillert J, Olsson T, Kockum I, Linden M, et al
European journal of human genetics : EJHG 2011;19(10):1100-3

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS
Freedman Ms, Bar-or A, Oger J, Traboulsee A, Patry D, Young C, et al
Neurology 2011;77(16):1551-60

Appendicectomy and multiple sclerosis risk
Roshanisefat H, Bahmanyar S, Hillert J, Olsson T, Montgomery Sm
European journal of neurology 2011;18(4):667-9

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
Holmen C, Piehl F, Hillert J, Fogdell-hahn A, Lundkvist M, Karlberg E, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2011;17(6):708-19

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course
Khademi M, Kockum I, Andersson Ml, Iacobaeus E, Brundin L, Sellebjerg F, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2011;17(3):335-43

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer Cc, et al
Nature 2011;476(7359):214-9

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
Kappos L, Bates D, Edan G, Eraksoy M, Garcia-merino A, Grigoriadis N, et al
The Lancet. Neurology 2011;10(8):745-58

No evidence of IL21 association with multiple sclerosis in a Swedish population
Linden M, Nohra R, Sundqvist E, Khademi M, Hillert J, Alfredsson L, et al
Tissue antigens 2011;78(4):271-4

No influence on disease progression of non-HLA susceptibility genes in MS
Lundstrom W, Greiner E, Lundmark F, Westerlind H, Smestad C, Lorentzen Ar, et al
Journal of neuroimmunology 2011;237(1-2):98-100

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab
Sorensen Ps, Jensen Pe, Haghikia A, Lundkvist M, Vedeler C, Sellebjerg F, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2011;17(9):1074-8

Randomized trial of oral teriflunomide for relapsing multiple sclerosis
O'connor P, Wolinsky Js, Confavreux C, Comi G, Kappos L, Olsson Tp, et al
The New England journal of medicine 2011;365(14):1293-303

Shift work at young age is associated with increased risk for multiple sclerosis
Hedstrom Ak, Akerstedt T, Hillert J, Olsson T, Alfredsson L
Annals of neurology 2011;70(5):733-41

Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis
Hedstrom Ak, Sundqvist E, Baarnhielm M, Nordin N, Hillert J, Kockum I, et al
Brain : a journal of neurology 2011;134(Pt 3):653-64

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study
Piehl F, Holmen C, Hillert J, Olsson T
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2011;31 Suppl 3():289-93

The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis
Iacobaeus E, Amoudruz P, Strom M, Khademi M, Brundin L, Hillert J, et al
PloS one 2011;6(5):e19138-

A longitudinal observational study of brain atrophy rate reflecting four decades of multiple sclerosis: a comparison of serial 1D, 2D, and volumetric measurements from MRI images
Martola J, Bergstrom J, Fredrikson S, Stawiarz L, Hillert J, Zhang Y, et al
Neuroradiology 2010;52(2):109-17

Alternative splicing of interleukin-7 (IL-7) and interleukin-7 receptor alpha (IL-7Ralpha) in peripheral blood from patients with multiple sclerosis (MS)
Rane L, Vudattu N, Bourcier K, Graniar E, Hillert J, Seyfert V, et al
Journal of neuroimmunology 2010;222(1-2):82-6

A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis
Mero Il, Lorentzen Ar, Ban M, Smestad C, Celius Eg, Aarseth Jh, et al
European journal of human genetics : EJHG 2010;18(4):502-4

CANCER RISK AMONG PATIENTS WITH MULTIPLE SCLEROSIS AND THEIR PARENTS Reply
Bahmanyar S, Montgomery Sm, Hillert J, Ekbom A, Olsson T
NEUROLOGY 2010;74(7):615-615

Confirmation of association between multiple sclerosis and CYP27B1
Sundqvist E, Baarnhielm M, Alfredsson L, Hillert J, Olsson T, Kockum I
European journal of human genetics : EJHG 2010;18(12):1349-52

Different HLA-DRB1 allele distributions in distinct clinical subgroups of sarcoidosis patients
Grunewald J, Brynedal B, Darlington P, Nisell M, Cederlund K, Hillert J, et al
Respiratory research 2010;11():25-

Gene expression profiling in multiple sclerosis: a disease of the central nervous system, but with relapses triggered in the periphery?
Brynedal B, Khademi M, Wallstrom E, Hillert J, Olsson T, Duvefelt K
Neurobiology of disease 2010;37(3):613-21

Genetic variants of CC chemokine genes in experimental autoimmune encephalomyelitis, multiple sclerosis and rheumatoid arthritis
Ockinger J, Stridh P, Beyeen Ad, Lundmark F, Seddighzadeh M, Oturai A, et al
Genes and immunity 2010;11(2):142-54

IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci
International Multiple Sclerosis Genetics Conssortium (imsgc)
Genes and immunity 2010;11(5):397-405

IL-22RA2 associates with multiple sclerosis and macrophage effector mechanisms in experimental neuroinflammation
Beyeen Ad, Adzemovic Mz, Ockinger J, Stridh P, Becanovic K, Laaksonen H, et al
Journal of immunology (Baltimore, Md. : 1950) 2010;185(11):6883-90

Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta
Sominanda A, Lundkvist M, Fogdell-hahn A, Hemmer B, Hartung Hp, Hillert J, et al
Archives of neurology 2010;67(9):1095-101

Lack of support for association between the KIF1B rs10492972[C] variant and multiple sclerosis
International Multiple Sclerosis Genetics Consortium (imsgc), Booth Dr, Heard Rn, Stewart Gj, Cox M, Scott Rj, et al
Nature genetics 2010;42(6):469-70

MGAT5 alters the severity of multiple sclerosis
Brynedal B, Wojcik J, Esposito F, Debailleul V, Yaouanq J, Martinelli-boneschi F, et al
Journal of neuroimmunology 2010;220(1-2):120-4

Multiple sclerosis in a family on the Faroe Islands
Binzer S, Imrell K, Binzer M, Vang S, Rogvi-hansen B, Hillert J, et al
ACTA NEUROLOGICA SCANDINAVICA 2010;121(6):432-432

Multiple sclerosis in a family on the Faroe Islands
Binzer S, Imrell K, Binzer M, Vang S, Rogvi-hansen B, Hillert J, et al
Acta neurologica Scandinavica 2010;121(1):16-9

Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta
Lundkvist M, Greiner E, Hillert J, Fogdell-hahn A
Multiple sclerosis (Houndmills, Basingstoke, England) 2010;16(7):796-800

Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis
Cunningham A, Gottberg K, Von Koch L, Hillert J
Acta neurologica Scandinavica 2010;121(3):154-60

RGMA and IL21R show association with experimental inflammation and multiple sclerosis
Nohra R, Beyeen Ad, Guo Jp, Khademi M, Sundqvist E, Hedreul Mt, et al
Genes and immunity 2010;11(4):279-93

The genetics of multiple sclerosis
Hillert J
Results and problems in cell differentiation 2010;51():1-19

Two HLA class I genes independently associated with multiple sclerosis
Link J, Lorentzen Ar, Kockum I, Duvefelt K, Lie Ba, Celius Eg, et al
Journal of neuroimmunology 2010;226(1-2):172-6

A role for VAV1 in experimental autoimmune encephalomyelitis and multiple sclerosis
Jagodic M, Colacios C, Nohra R, Dejean As, Beyeen Ad, Khademi M, et al
Science translational medicine 2009;1(10):10ra21-

A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke
Gudbjartsson Df, Holm H, Gretarsdottir S, Thorleifsson G, Walters Gb, Thorgeirsson G, et al
Nature genetics 2009;41(8):876-8

Cancer risk among patients with multiple sclerosis and their parents
Bahmanyar S, Montgomery Sm, Hillert J, Ekbom A, Olsson T
Neurology 2009;72(13):1170-7

Common CCR 5 polymorphism in stroke: the CCR 5 delta32 polymorphism differentiates cardioembolism from other aetiologies of ischaemic cerebrovascular diseases
Kostulas N, Markaki I, Kostulas V, Hillert J, Kostulas K
Scandinavian journal of immunology 2009;70(5):475-80

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al
Lancet (London, England) 2009;374(9700):1503-11

HLA-DRB115 and cerebrospinal-fluid-specific oligoclonal immunoglobulin G bands lower age at attainment of important disease milestones in multiple sclerosis
Imrell K, Greiner E, Hillert J, Masterman T
Journal of neuroimmunology 2009;210(1-2):128-30

HLA-DRB1 and month of birth in multiple sclerosis
Ramagopalan Sv, Link J, Byrnes Jk, Dyment Da, Giovannoni G, Hintzen Rq, et al
Neurology 2009;73(24):2107-11

MYO9B polymorphisms in multiple sclerosis
Kemppinen A, Suvela M, Tienari Pj, Elovaara I, Koivisto K, Pirttila T, et al
European journal of human genetics : EJHG 2009;17(6):840-3

Neutralizing antibodies against interferon β: fluctuation is modest and titre dependent
Sominanda A, Hillert J, Fogdell-hahn A
European journal of neurology 2009;16(1):21-6

One-dimensional-ratio measures of atrophy progression in multiple sclerosis as evaluated by longitudinal magnetic resonance imaging
Martola J, Stawiarz L, Fredrikson S, Hillert J, Bergstrom J, Flodmark O, et al
Acta radiologica (Stockholm, Sweden : 1987) 2009;50(8):924-32

Risk for multiple sclerosis in relatives and spouses of patients diagnosed with autoimmune and related conditions
Hemminki K, Li X, Sundquist J, Hillert J, Sundquist K
Neurogenetics 2009;10(1):5-11

The expanding genetic overlap between multiple sclerosis and type I diabetes
International Multiple Sclerosis Genetics Consortium (imsgc)
Genes and immunity 2009;10(1):11-4

Use of a genetic isolate to identify rare disease variants: C7 on 5p associated with MS
Kallio Sp, Jakkula E, Purcell S, Suvela M, Koivisto K, Tienari Pj, et al
Human molecular genetics 2009;18(9):1670-83

A common haplotype of the C-C chemokine receptor 2 gene and HLA-DRB1*0301 are independent genetic risk factors for Löfgren's syndrome
Spagnolo P, Sato H, Grunewald J, Brynedal B, Hillert J, Mana J, et al
Journal of internal medicine 2008;264(5):433-41

A longitudinal study of variations in and predictors of fatigue in multiple sclerosis
Johansson S, Ytterberg C, Hillert J, Widen Holmqvist L, Von Koch L
Journal of neurology, neurosurgery, and psychiatry 2008;79(4):454-7

Comparative study of four different assays for the detection of binding antibodies against interferon-beta
Gneiss C, Brugger M, Millonig A, Fogdell-hahn A, Rudzki D, Hillert J, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2008;14(6):830-6

Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients
Vas A, Shchukin Y, Karrenbauer Vd, Cselenyi Z, Kostulas K, Hillert J, et al
Journal of the neurological sciences 2008;264(1-2):9-17

Genetic profile of ischemic cerebrovascular disease and carotid stenosis
Kostulas K, Brophy Vh, Moraitis K, Manolescu A, Kostulas V, Gretarsdottir S, et al
Acta neurologica Scandinavica 2008;118(3):146-52

Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis
Aulchenko Ys, Hoppenbrouwers Ia, Ramagopalan Sv, Broer L, Jafari N, Hillert J, et al
Nature genetics 2008;40(12):1402-3

Impression of clinical worsening fails to predict interferon-beta neutralizing antibody status
Rot U, Sominanda A, Fogdell-hahn A, Hillert J
The Journal of international medical research 2008;36(6):1418-25

Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations
Kristjansdottir G, Sandling Jk, Bonetti A, Roos Im, Milani L, Wang C, et al
Journal of medical genetics 2008;45(6):362-9

In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent
Sominanda A, Hillert J, Fogdell-hahn A
Journal of neurology, neurosurgery, and psychiatry 2008;79(1):57-62

Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis
Thangarajh M, Gomez-rial J, Hedstrom Ak, Hillert J, Alvarez-cermeno Jc, Masterman T, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2008;14(9):1208-13

Maternal smoking during pregnancy and multiple sclerosis amongst offspring
Montgomery Sm, Bahmanyar S, Hillert J, Ekbom A, Olsson T
European journal of neurology 2008;15(12):1395-9

Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden
Kobelt G, Berg J, Lindgren P, Jonsson B, Stawiarz L, Hillert J
Multiple sclerosis (Houndmills, Basingstoke, England) 2008;14(5):679-90

Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis
Farrell R, Bendtzen K, Bertolotto A, Clark B, Comabella M, Deisenhammer F, et al
The Journal of international medical research 2008;36(1):204-8

Rate of ventricular enlargement in multiple sclerosis: a nine-year magnetic resonance imaging follow-up study
Martola J, Stawiarz L, Fredrikson S, Hillert J, Bergstrom J, Flodmark O, et al
Acta radiologica (Stockholm, Sweden : 1987) 2008;49(5):570-9

Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke
Gretarsdottir S, Thorleifsson G, Manolescu A, Styrkarsdottir U, Helgadottir A, Gschwendtner A, et al
Annals of neurology 2008;64(4):402-9

The genetics of multiple sclerosis and its experimental models
Olsson T, Hillert J
Current opinion in neurology 2008;21(3):255-60

The interleukin 23 receptor gene in multiple sclerosis: a case-control study
Roos Im, Kockum I, Hillert J
Journal of neuroimmunology 2008;194(1-2):173-80

The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm
Helgadottir A, Thorleifsson G, Magnusson Kp, Gretarsdottir S, Steinthorsdottir V, Manolescu A, et al
Nature genetics 2008;40(2):217-24

The SH2D2A gene and susceptibility to multiple sclerosis
Lorentzen Ar, Smestad C, Lie Ba, Oturai Ab, Akesson E, Saarela J, et al
Journal of neuroimmunology 2008;197(2):152-8

A follow-up study of Nordic multiple sclerosis candidate gene regions
Datta P, Harbo Hf, Ryder Lp, Akesson E, Benedikz J, Celius Eg, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2007;13(5):584-9

An association study of two functional promotor polymorphisms in the myeloperoxidase (MPO) gene in multiple sclerosis
Lundmark F, Salter H, Hillert J
Multiple sclerosis (Houndmills, Basingstoke, England) 2007;13(6):697-700

A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis
Thangarajh M, Masterman T, Hillert J, Moerk S, Jonsson R
Scandinavian journal of immunology 2007;65(1):92-8

[Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo]
Tedeholm H, Skoog B, Hillert J, Runmarker B, Stawiarz L, Oluf A
Läkartidningen 2007;104(22):1684-8

Familial effects on the clinical course of multiple sclerosis
Hensiek Ae, Seaman Sr, Barcellos Lf, Oturai A, Eraksoi M, Cocco E, et al
Neurology 2007;68(5):376-83

High concurrent presence of disability in multiple sclerosis. Associations with perceived health
Johansson S, Ytterberg C, Claesson Im, Lindberg J, Hillert J, Andersson M, et al
Journal of neurology 2007;254(6):767-73

[High societal costs of brain diseases. Extremely small resources allocated to research on prevention and treatment]
Sobocki P, Allgulander C, Hillert J, Jonsson B
Läkartidningen 2007;104(20-21):1590-4

HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis
Brynedal B, Duvefelt K, Jonasdottir G, Roos Im, Akesson E, Palmgren J, et al
PloS one 2007;2(7):e664-

Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity
Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, Fogdell-hahn A
Multiple sclerosis (Houndmills, Basingstoke, England) 2007;13(2):208-14

ITGA4 polymorphisms and susceptibility to multiple sclerosis
O'doherty C, Roos Im, Antiguedad A, Aransay Am, Hillert J, Vandenbroeck K
Journal of neuroimmunology 2007;189(1-2):151-7

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report
Hartung Hp, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, et al
Journal of neurology 2007;254(7):827-37

PDE4D and ALOX5AP genetic variants and risk for Ischemic Cerebrovascular Disease in Sweden
Kostulas K, Gretarsdottir S, Kostulas V, Manolescu A, Helgadottir A, Thorleifsson G, et al
Journal of the neurological sciences 2007;263(1-2):113-7

Progression of non-age-related callosal brain atrophy in multiple sclerosis: a 9-year longitudinal MRI study representing four decades of disease development
Martola J, Stawiarz L, Fredrikson S, Hillert J, Bergstrom J, Flodmark O, et al
Journal of neurology, neurosurgery, and psychiatry 2007;78(4):375-80

The expression of BAFF-binding receptors is not altered in multiple sclerosis or myasthenia gravis
Thangarajh M, Kisiswa L, Pirskanen R, Hillert J
Scandinavian journal of immunology 2007;65(5):461-6

The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients
Smestad C, Brynedal B, Jonasdottir G, Lorentzen Ar, Masterman T, Akesson E, et al
European journal of neurology 2007;14(8):835-40

Variants conferring risk of atrial fibrillation on chromosome 4q25
Gudbjartsson Df, Arnar Do, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A, et al
Nature 2007;448(7151):353-7

Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis
Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallstrom E, Khademi M, et al
Nature genetics 2007;39(9):1108-13

A genome-wide scan and HCRTR2 candidate gene analysis in a European cluster headache cohort
Baumber L, Sjostrand C, Leone M, Harty H, Bussone G, Hillert J, et al
Neurology 2006;66(12):1888-93

APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers
Burwick Rm, Ramsay Pp, Haines Jl, Hauser Sl, Oksenberg Jr, Pericak-vance Ma, et al
Neurology 2006;66(9):1373-83

Association analysis of the LAG3 and CD4 genes in multiple sclerosis in two independent populations
Lundmark F, Harbo Hf, Celius Eg, Saarela J, Datta P, Oturai A, et al
Journal of neuroimmunology 2006;180(1-2):193-8

Blockade of chemokine signaling in patients with multiple sclerosis
Zipp F, Hartung Hp, Hillert J, Schimrigk S, Trebst C, Stangel M, et al
Neurology 2006;67(10):1880-3

Gene expression profiling in cluster headache: a pilot microarray study
Sjostrand C, Duvefelt K, Steinberg A, Remahl In, Waldenlind E, Hillert J
Headache 2006;46(10):1518-34

Genetically determined susceptibility to neurodegeneration is associated with expression of inflammatory genes
Swanberg M, Duvefelt K, Diez M, Hillert J, Olsson T, Piehl F, et al
Neurobiology of disease 2006;24(1):67-88

Increased soluble 4-1BB ligand (4-1BBL) levels in peripheral blood of patients with multiple sclerosis
Liu Gz, Gomes Ac, Putheti P, Karrenbauer V, Kostulas K, Press R, et al
Scandinavian journal of immunology 2006;64(4):412-9

Multiple sclerosis: postlinkage genetics
Hillert J
Clinical neurology and neurosurgery 2006;108(3):220-2

Multiple sclerosis with and without CSF bands: clinically indistinguishable but immunogenetically distinct
Imrell K, Landtblom Am, Hillert J, Masterman T
Neurology 2006;67(6):1062-4

The thymus is a source of B-cell-survival factors-APRIL and BAFF-in myasthenia gravis
Thangarajh M, Masterman T, Helgeland L, Rot U, Jonsson Mv, Eide Ge, et al
Journal of neuroimmunology 2006;178(1-2):161-6

A high-density screen for linkage in multiple sclerosis
Sawcer S, Ban M, Maranian M, Yeo Tw, Compston A, Kirby A, et al
American journal of human genetics 2005;77(3):454-67

Familial cluster headache. Is atypical cluster headache in family members part of the clinical spectrum?
Sjostrand C, Russell Mb, Ekbom K, Hillert J, Waldenlind E
Cephalalgia : an international journal of headache 2005;25(11):1068-77

Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis
Thangarajh M, Masterman T, Rot U, Duvefelt K, Brynedal B, Karrenbauer Vd, et al
Journal of neuroimmunology 2005;167(1-2):210-4

MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction
Swanberg M, Lidman O, Padyukov L, Eriksson P, Akesson E, Jagodic M, et al
Nature genetics 2005;37(5):486-94

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity
Roxburgh Rh, Seaman Sr, Masterman T, Hensiek Ae, Sawcer Sj, Vukusic S, et al
Neurology 2005;64(7):1144-51

Two genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis
Zhang Z, Duvefelt K, Svensson F, Masterman T, Jonasdottir G, Salter H, et al
Genes and immunity 2005;6(2):145-52

A NOTCH4 association with multiple sclerosis is secondary to HLA-DR*1501
Duvefelt K, Anderson M, Fogdell-hahn A, Hillert J
Tissue antigens 2004;63(1):13-20

Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs
Oturai Ab, Ryder Lp, Fredrikson S, Myhr Km, Celius Eg, Harbo Hf, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(1):5-8

Diagnostic use of cerebral and extracerebral oxysterols
Leoni V, Masterman T, Mousavi Fs, Wretlind B, Wahlund Lo, Diczfalusy U, et al
Clinical chemistry and laboratory medicine 2004;42(2):186-91

Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis
Thangarajh M, Gomes A, Masterman T, Hillert J, Hjelmstrom P
Journal of neuroimmunology 2004;152(1-2):183-90

Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis
Harbo Hf, Lie Ba, Sawcer S, Celius Eg, Dai Kz, Oturai A, et al
Tissue antigens 2004;63(3):237-47

Increased expression of caspase-1 and interleukin-18 in peripheral blood mononuclear cells in patients with multiple sclerosis
Huang Wx, Huang P, Hillert J
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(5):482-7

Modes of action of HLA-DR susceptibility specificities in multiple sclerosis
Modin H, Olsson W, Hillert J, Masterman T
American journal of human genetics 2004;74(6):1321-2

Decreased levels of CD95 and caspase-8 mRNA in multiple sclerosis patients with gadolinium-enhancing lesions on MRI
Gomes Ac, Morris M, Stawiarz L, Jonsson G, Putheti P, Bronge L, et al
Neuroscience letters 2003;352(2):101-4

Genome-wide linkage screen of a consanguineous multiple sclerosis kinship
Modin H, Masterman T, Thorlacius T, Stefansson M, Jonasdottir A, Stefansson K, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(2):128-34

Genome-wide TDT analysis in a localized population with a high prevalence of multiple sclerosis indicates the importance of a region on chromosome 14q
Giedraitis V, Modin H, Callander M, Landtblom Am, Fossdal R, Stefansson K, et al
Genes and immunity 2003;4(8):559-63

Intercellular adhesion molecule-1 K469E polymorphism: study of association with multiple sclerosis
Nejentsev S, Laaksonen M, Tienari Pj, Fernandez O, Cordell H, Ruutiainen J, et al
Human immunology 2003;64(3):345-9

Multiple sclerosis: a study of chemokine receptors and regulatory T cells in relation to MRI variables
Putheti P, Morris M, Stawiarz L, Teleshova N, Kivisakk P, Pashenkov M, et al
European journal of neurology 2003;10(5):529-35

Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients
Harbo Hf, Datta P, Oturai A, Ryder Lp, Sawcer S, Setakis E, et al
Journal of neuroimmunology 2003;143(1-2):101-6

Upregulation of the apoptosis regulators cFLIP, CD95 and CD95 ligand in peripheral blood mononuclear cells in relapsing-remitting multiple sclerosis
Gomes Ac, Jonsson G, Mjornheim S, Olsson T, Hillert J, Grandien A
Journal of neuroimmunology 2003;135(1-2):126-34

A genome-wide screen for linkage in Nordic sib-pairs with multiple sclerosis
Akesson E, Oturai A, Berg J, Fredrikson S, Andersen O, Harbo Hf, et al
Genes and immunity 2002;3(5):279-85

Analysis of a CD40 ligand dinucleotide microsatellite in multiple sclerosis
Dai Y, Masterman T, Huang W, Hillert J
European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics 2002;29(2):81-5

Analysis of nitric oxide synthase genes in cluster headache
Sjostrand C, Modin H, Masterman T, Ekbom K, Waldenlind E, Hillert J
Cephalalgia : an international journal of headache 2002;22(9):758-64

Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial
Killestein J, Olsson T, Wallstrom E, Svenningsson A, Khademi M, Blumhardt Ld, et al
Annals of neurology 2002;51(4):467-74

APOE genotypes and disease severity in multiple sclerosis
Masterman T, Zhang Z, Hellgren D, Salter H, Anvret M, Lilius L, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2002;8(2):98-103

Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis
Leoni V, Masterman T, Diczfalusy U, De Luca G, Hillert J, Bjorkhem I
Neuroscience letters 2002;331(3):163-6

CTLA4 dimorphisms and the multiple sclerosis phenotype
Masterman T, Ligers A, Zhang Z, Hellgren D, Salter H, Anvret M, et al
Journal of neuroimmunology 2002;131(1-2):208-12

HLA-DR15 and age at onset in multiple sclerosis
Masterman T, Hillert J
European journal of neurology 2002;9(2):179-80

Inflammation in multiple sclerosis: the good, the bad, and the complex
Martino G, Adorini L, Rieckmann P, Hillert J, Kallmann B, Comi G, et al
The Lancet. Neurology 2002;1(8):499-509

Sharing of a conserved haplotype suggests a susceptibility gene for multiple sclerosis at chromosome 17p11
He B, Giedraitis V, Ligers A, Binzer M, Andersen Pm, Forsgren L, et al
European journal of human genetics : EJHG 2002;10(4):271-5

Analysis of an interferon-gamma gene dinucleotide-repeat polymorphism in Nordic multiple sclerosis patients
Dai Y, Masterman T, Huang Wx, Sandberg-wollheim M, Laaksonen M, Harbo Hf, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2001;7(3):157-63

CACNA1A gene polymorphisms in cluster headache
Sjostrand C, Giedratis V, Ekbom K, Waldenlind E, Hillert J
Cephalalgia : an international journal of headache 2001;21(10):953-8

Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation
Giedraitis V, He B, Huang Wx, Hillert J
Journal of neuroimmunology 2001;112(1-2):146-52

CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms
Ligers A, Teleshova N, Masterman T, Huang Wx, Hillert J
Genes and immunity 2001;2(3):145-52

Does 77C-->G in PTPRC modify autoimmune disorders linked to the major histocompatibility locus?
Vorechovsky I, Kralovicova J, Tchilian E, Masterman T, Zhang Z, Ferry B, et al
Nature genetics 2001;29(1):22-3

Evidence of linkage with HLA-DR in DRB1*15-negative families with multiple sclerosis
Ligers A, Dyment Da, Willer Cj, Sadovnick Ad, Ebers G, Risch N, et al
American journal of human genetics 2001;69(4):900-3

Genetic susceptibility to MS: a second stage analysis in Canadian MS families
Dyment Da, Willer Cj, Scott B, Armstrong H, Ligers A, Hillert J, et al
Neurogenetics 2001;3(3):145-51

Linkage analysis in multiple sclerosis of chromosomal regions syntenic to experimental autoimmune disease loci
Xu C, Dai Y, Lorentzen Jc, Dahlman I, Olsson T, Hillert J
European journal of human genetics : EJHG 2001;9(6):458-63

Linkage analysis suggests a region of importance for multiple sclerosis in 3p14-13
Dai Y, Xu C, Holmberg M, Oturai A, Fredrikson S, Sandberg-wollheim M, et al
Genes and immunity 2001;2(8):451-4

No linkage or association of the nitric oxide synthase genes to multiple sclerosis
Modin H, Dai Y, Masterman T, Svejgaard A, Sorensen Ps, Oturai A, et al
Journal of neuroimmunology 2001;119(1):95-100

The T cell regulator gene SH2D2A contributes to the genetic susceptibility of multiple sclerosis
Dai Kz, Harbo Hf, Celius Eg, Oturai A, Sorensen Ps, Ryder Lp, et al
Genes and immunity 2001;2(5):263-8

Apoptosis mediators fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS
Huang W-x , Huang Mp, Gomes Ma, Hillert J
Neurology 2000;55(7):928-34

Decreased mRNA expression of TNF-alpha and IL-10 in non-stimulated peripheral blood mononuclear cells in myasthenia gravis
Huang Wx, Huang P, Fredrikson S, Pirskanen R, Hillert J
European journal of neurology 2000;7(2):195-202

HLA-DR15 is associated with lower age at onset in multiple sclerosis
Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hillert J
Annals of neurology 2000;48(2):211-9

Linkage analysis of a candidate region in Scandinavian sib pairs with multiple sclerosis reveals linkage to chromosome 17q
Larsen F, Oturai A, Ryder Lp, Madsen Ho, Hillert J, Fredrikson S, et al
Genes and immunity 2000;1(7):456-9

MS genetics: recent Scandinavian efforts
Hillert J
Journal of neurovirology 2000;6 Suppl 2():S15-7

Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease
Fogdell-hahn A, Ligers A, Gronning M, Hillert J, Olerup O
Tissue antigens 2000;55(2):140-8

PECAM1, MPO and PRKAR1A at chromosome 17q21-q24 and susceptibility for multiple sclerosis in Sweden and Sardinia
Nelissen I, Fiten P, Vandenbroeck K, Hillert J, Olsson T, Marrosu Mg, et al
Journal of neuroimmunology 2000;108(1-2):153-9

Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases
Bretillon L, Siden A, Wahlund Lo, Lutjohann D, Minthon L, Crisby M, et al
Neuroscience letters 2000;293(2):87-90

Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis
Nelissen I, Vandenbroeck K, Fiten P, Hillert J, Olsson T, Marrosu Mg, et al
Journal of neuroimmunology 2000;105(1):58-63

Systemic upregulation of CD40 and CD40 ligand mRNA expression in multiple sclerosis
Huang Wx, Huang P, Hillert J
Multiple sclerosis (Houndmills, Basingstoke, England) 2000;6(2):61-5

An angiotensin-converting enzyme gene polymorphism suggests a genetic distinction between ischaemic stroke and carotid stenosis
Kostulas K, Huang Wx, Crisby M, Jin Yp, He B, Lannfelt L, et al
European journal of clinical investigation 1999;29(6):478-83

Association and linkage analysis of candidate chromosomal regions in multiple sclerosis: indication of disease genes in 12q23 and 7ptr-15
Xu C, Dai Y, Fredrikson S, Hillert J
European journal of human genetics : EJHG 1999;7(2):110-6

CTLA-4 dimorphisms in gammopathy-associated peripheral neuropathy
Masterma T, Ligers A, Olerup O, Vrethem M, Hillert J
European journal of neurology 1999;6(4):491-3

Cytokine analysis in multiple sclerosis by competitive RT - PCR: A decreased expression of IL-10 and an increased expression of TNF-alpha in chronic progression
Huang Wx, Huang P, Link H, Hillert J
Multiple sclerosis (Houndmills, Basingstoke, England) 1999;5(5):342-8

Linkage and association analysis of susceptibility regions on chromosomes 5 and 6 in 106 Scandinavian sibling pair families with multiple sclerosis
Oturai A, Larsen F, Ryder Lp, Madsen Ho, Hillert J, Fredrikson S, et al
Annals of neurology 1999;46(4):612-6

Microsatellite polymorphisms in the gene promoter of monocyte chemotactic protein-3 and analysis of the association between monocyte chemotactic protein-3 alleles and multiple sclerosis development
Fiten P, Vandenbroeck K, Dubois B, Van Coillie E, Nelissen I, Van Damme J, et al
Journal of neuroimmunology 1999;95(1-2):195-201

Molecular cloning of a full-length cDNA for human type 3 adenylyl cyclase and its expression in human islets
Yang B, He B, Abdel-halim Sm, Tibell A, Brendel Md, Bretzel Rg, et al
Biochemical and biophysical research communications 1999;254(3):548-51

Mutation screening of the interferon-gamma gene as a candidate gene for multiple sclerosis
Giedraitis V, He B, Hillert J
European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics 1999;26(4):257-9

The CTLA-4 gene is associated with multiple sclerosis
Ligers A, Xu C, Saarinen S, Hillert J, Olerup O
Journal of neuroimmunology 1999;97(1-2):182-90

Absence of linkage with the neuronal nitric oxide synthase (NOS1) gene in 41 multiplex Swedish MS families
Xu C, Hillert J
EUROPEAN JOURNAL OF NEUROLOGY 1998;5(4):393-396

A methylenetetrahydrofolate reductase gene polymorphism in ischaemic stroke and in carotid artery stenosis
Kostulas K, Crisby M, Huang Wx, Lannfelt L, Hagenfeldt L, Eggertsen G, et al
European journal of clinical investigation 1998;28(4):285-9

Linkage and association analysis of genes encoding cytokines and myelin proteins in multiple sclerosis
He B, Xu C, Yang B, Landtblom Am, Fredrikson S, Hillert J
Journal of neuroimmunology 1998;86(1):13-9

Mutations in the promoter of adenylyl cyclase (AC)-III gene, overexpression of AC-III mRNA, and enhanced cAMP generation in islets from the spontaneously diabetic GK rat model of type 2 diabetes
Abdel-halim Sm, Guenifi A, He B, Yang B, Mustafa M, Hojeberg B, et al
Diabetes 1998;47(3):498-504

Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings
Soderstrom M, Ya-ping J, Hillert J, Link H
Neurology 1998;50(3):708-14

The myelin basic protein gene in multiple sclerosis: identification of discrete alleles of a 1.3 kb tetranucleotide repeat sequence
He B, Yang B, Lundahl J, Fredrikson S, Hillert J
Acta neurologica Scandinavica 1998;97(1):46-51

Treatment with P2 protein peptide 57-81 by nasal route is effective in Lewis rat experimental autoimmune neuritis
Zou Lp, Zhu J, Deng Gm, Levi M, Wahren B, Diab A, et al
Journal of neuroimmunology 1998;85(2):137-45

A methylenetetrahydrofolate reductase gene polymorphism in multiple sclerosis
Huang Wx, He B, Hillert J
European journal of neurology 1997;4(2):185-7

Linkage analysis of HLA class II genes in Swedish multiplex families with multiple sclerosis
Fogdell A, Olerup O, Fredrikson S, Vrethem M, Hillert J
Neurology 1997;48(3):758-62

Lipoprotein lipase gene polymorphisms in ischaemic stroke and carotid stenosis
Huang P, Kostulas K, Huang Wx, Crisby M, Kostulas V, Hillert J
European journal of clinical investigation 1997;27(9):740-2

No linkage or association of a VNTR marker in the junction region of the immunoglobulin heavy chain genes in multiple sclerosis
Ligers A, He B, Fogdell-hahn A, Olerup O, Hillert J
European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics 1997;24(4):259-64

An interleukin 1-receptor-antagonist gene polymorphism is not associated with multiple sclerosis
Huang Wx, He B, Hillert J
Journal of neuroimmunology 1996;67(2):143-4

Distribution of HLA-Dw2 in optic neuritis and multiple sclerosis indicates heterogeneity
Hillert J, Kall T, Olerup O, Soderstrom M
Acta neurologica Scandinavica 1996;94(3):161-6

[Intensifying the care of MS-patients]
Fredrikson S, Hillert J, Link H, Soderstrom M, Isberg B
Läkartidningen 1996;93(11):1015-20

Expression of IFN-gamma, IL-4, and TGF-beta in multiple sclerosis in relation to HLA-Dw2 phenotype and stage of disease
Soderstrom M, Hillert J, Link J, Navikas V, Fredrikson S, Link H
Multiple sclerosis (Houndmills, Basingstoke, England) 1995;1(3):173-80

The multiple sclerosis- and narcolepsy-associated HLA class II haplotype includes the DRB5*0101 allele
Fogdell A, Hillert J, Sachs C, Olerup O
Tissue antigens 1995;46(4):333-6

Tumor necrosis factor alpha-308 alleles in multiple sclerosis and optic neuritis
He B, Navikas V, Lundahl J, Soderstrom M, Hillert J
Journal of neuroimmunology 1995;63(2):143-7

Visa alla publikationer

Karta